Prellis Biologics, Inc.

Prellis Biologics, Inc. is a biotechnology company focused on advanced antibody discovery technologies, utilizing innovative machine learning combined with 3D bioprinted lymph node organoids to create fully human antibodies for therapeutic applications. Founded in 2016 and headquartered in San Francisco, US, Prellis Biologics specializes in developing proprietary antibody discovery technologies. The company has raised a total of USD 17.

00 mn in funding, with the latest round being a Series C completed on June 22, 2022, co-led by Avidity Partners and Celesta Capital, alongside other notable investors such as Khosla Ventures and True Ventures. Melanie M. serves as the CEO and co-founder, having previously founded other ventures in the biotechnology sector. Prellis Biologics specializes in advanced antibody discovery technologies through its proprietary EXIS™ platform, which leverages machine learning alongside 3D bioprinted lymph node organoids.

This technology enables the rapid and scalable identification of fully human antibodies, which are designed for therapeutic use against various diseases. The company provides these innovations primarily to biotech and pharmaceutical firms aiming to enhance their therapeutic pipelines, particularly in North America and Europe. Prellis Biologics generates revenue through partnerships and collaborations with leading biotech and pharmaceutical companies, typically structured around licensing agreements and collaborative research deals. Clients pay upfront fees, milestone payments, and royalties on future product sales, allowing them to utilize Prellis' technologies in their development processes.

The EXIS™ platform and associated services form a core part of these transactions, focusing on expedited drug development and reduced immunogenicity in therapeutic candidates. Following the Series C funding round in June 2022, Prellis Biologics plans to expand its research and development of the EXIS platform, further enhancing its capabilities in antibody discovery. The company aims to penetrate new markets, particularly targeting European regions by 2024, to meet the growing demand for innovative drug discovery solutions. The recent funding will be allocated to bolster R&D efforts, ensuring the continuous advancement of its product offerings.